Genmab A/S (LON:0MGB)
London · Delayed Price · Currency is GBP · Price in DKK 2,011.50
-4.89 (-0.24%)
At close: Dec 18, 2025
Genmab Employees
Genmab had 2,682 employees as of December 31, 2024. The number of employees increased by 478 or 21.69% compared to the previous year.
Employees
2,682
Change (1Y)
478
Growth (1Y)
21.69%
Revenue / Employee
1.07M GBP
Profits / Employee
439.33K GBP
Market Cap
14.87B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2,682 | 478 | 21.69% |
| Dec 31, 2023 | 2,204 | 544 | 32.77% |
| Dec 31, 2022 | 1,660 | 448 | 36.96% |
| Dec 31, 2021 | 1,212 | 431 | 55.19% |
| Dec 31, 2020 | 781 | 233 | 42.52% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| HSBC Holdings | 211,304 |
| Unilever | 115,964 |
| BP p.l.c. | 100,500 |
| Shell | 96,000 |
| AstraZeneca | 94,300 |
| Barclays | 93,000 |
| GSK plc | 68,629 |
| Lloyds Banking Group | 61,228 |
Genmab News
- 8 days ago - Genmab Meets Conditions For $97/shr Merus Tender Offer - Nasdaq
- 9 days ago - Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period - Business Wire
- 9 days ago - Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period - GlobeNewsWire
- 9 days ago - Genmab A/S (GMAB) Discusses 2025 R&D Progress, ASH Data Review, and Strategic Pipeline Additions - Slideshow - Seeking Alpha
- 9 days ago - Genmab A/S (GMAB) Discusses 2025 R&D Progress, ASH Data Review, and Strategic Pipeline Additions Transcript - Seeking Alpha
- 10 days ago - Genmab to Hold 2025 R&D Update and ASH Data Review Meeting - GlobeNewsWire
- 12 days ago - Genmab (GMAB) Highlights Promising Results from EPCORE CLL-1 Trial - GuruFocus
- 12 days ago - Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT) - Business Wire